Medical Device | March 10, 2026
Codis expands UK manufacturing with groundbreaking spray dryer
The new equipment will be installed at Codis’ 400,000-square-foot Haverhill facility and is expected to be operational by 2027
The new equipment will be installed at Codis’ 400,000-square-foot Haverhill facility and is expected to be operational by 2027
The company will address the observations and respond to the U.S. FDA within the stipulated timeframe
ShunzymeX leverages a proprietary protease to streamline purification
The inspection concluded with zero observations, confirming the facility's compliance with current Good Manufacturing Practices
A next-generation, cell-based immunotherapy, CAR-T therapy engineers a patient’s own immune cells to detect and destroy cancer
VievePharm is renowned for its phytogenic formulations across livestock, equine, and pet care markets
TED?A9 is part of S.Biomedics’ expanding pipeline of stem-cell-based therapies, developed using the company’s proprietary targeted embryonic stem cell differentiation platform
The enhancements will improve environmental sustainability, strengthen material governance, and boost utility reliability
Operational leverage kicked in during the quarter, with adjusted EBITDA rising 21% year-on-year to Rs 147 crore
The Profit After Tax (PAT) for Q3 FY26 was Rs 49.68 crore, compared to Rs 46.78 crore in Q3 FY25
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
